Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years
Authors
Keywords
-
Journal
Alzheimers & Dementia
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-20
DOI
10.1002/alz.12745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years
- (2022) Hannah Stocker et al. Alzheimers & Dementia
- Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
- (2021) Antoine Leuzy et al. CURRENT OPINION IN NEUROLOGY
- Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
- (2021) Alexis Moscoso et al. JAMA Neurology
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
- (2021) Pratishtha Chatterjee et al. Translational Psychiatry
- Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
- (2021) Niklas Mattsson‐Carlgren et al. EMBO Molecular Medicine
- Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
- (2021) Pratishtha Chatterjee et al. Alzheimers & Dementia
- Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases
- (2021) Henrik Zetterberg JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
- (2021) Sebastian Palmqvist et al. NATURE MEDICINE
- Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
- (2021) Nicholas C. Cullen et al. Nature Communications
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
- (2021) Shorena Janelidze et al. JAMA Neurology
- Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
- (2021) Inge M. W. Verberk et al. Alzheimers & Dementia
- Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
- (2020) Frank de Wolf et al. BRAIN
- Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years
- (2020) H. Stocker et al. MOLECULAR PSYCHIATRY
- Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
- (2020) Nicolas R. Barthélemy et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease
- (2020) Christoforos Hadjichrysanthou et al. Alzheimers Research & Therapy
- Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
- (2020) Nicholas C. Cullen et al. Annals of Clinical and Translational Neurology
- Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
- (2020) Kumar B. Rajan et al. ANNALS OF NEUROLOGY
- Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
- (2020) Inge M. W. Verberk et al. Alzheimers Research & Therapy
- Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
- (2020) Alexis Moscoso et al. BRAIN
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
- (2020) Julia Stockmann et al. Alzheimers Research & Therapy
- Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
- (2020) Oskar Hansson et al. Annals of Clinical and Translational Neurology
- TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis
- (2020) Léon Beyer et al. Annals of Clinical and Translational Neurology
- Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment
- (2019) Patrick Oeckl et al. JOURNAL OF ALZHEIMERS DISEASE
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
- (2019) Oliver Preische et al. NATURE MEDICINE
- Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
- (2019) Nicholas J. Ashton et al. Acta Neuropathologica Communications
- Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease
- (2019) Philip S. J. Weston et al. Alzheimers Research & Therapy
- Incident depression and mortality among people with different types of dementia: results from a longitudinal cohort study
- (2019) Laura Perna et al. SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
- (2019) Suzanne E. Schindler et al. NEUROLOGY
- Neurofilament light chain — new potential for prediction and prognosis
- (2019) Ian Fyfe Nature Reviews Neurology
- Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors
- (2019) Hannah Stocker et al. Alzheimers & Dementia
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Amyloid blood biomarker detects Alzheimer's disease
- (2018) Andreas Nabers et al. EMBO Molecular Medicine
- Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer’s Disease
- (2016) Andreas Nabers et al. ANALYTICAL CHEMISTRY
- Interaction of the Heparin-Binding Consensus Sequence of β-Amyloid Peptides with Heparin and Heparin-Derived Oligosaccharides
- (2016) Khanh Nguyen et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Association between Oxidative Stress and Frailty in an Elderly German Population: Results from the ESTHER Cohort Study
- (2015) Kai-Uwe Saum et al. GERONTOLOGY
- An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids
- (2015) Andreas Nabers et al. Journal of Biophotonics
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- The Toxicity of Amyloid ß Oligomers
- (2012) Li Na Zhao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now